Lenvatinib/Pembrolizumab/Chemo Induces Inferior OS vs Pembrolizumab/Chemo in Previously Untreated NSCLC
January 5th 2024
Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.